<?xml version="1.0" encoding="UTF-8"?>
<p>As discussed above, nanotechnology started to be a critical player in the antiviral therapy. As mentioned by Ross et al. [
 <xref rid="B99-pharmaceutics-12-00171" ref-type="bibr">99</xref>], nanotechnology frees the current therapy payloads in terms of delivery across biological complex barriers, and could resolve the low bioavailability drawback as already stated in 
 <xref ref-type="sec" rid="sec3-pharmaceutics-12-00171">Section 3</xref>.
</p>
